These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 25416400)

  • 1. The rheumatoid arthritis treat-to-target trial: a cluster randomized trial within the Corrona rheumatology network.
    Harrold LR; Reed GW; Harrington JT; Barr CJ; Saunders KC; Gibofsky A; Greenberg JD; John A; Devenport J; Kremer JM
    BMC Musculoskelet Disord; 2014 Nov; 15():389. PubMed ID: 25416400
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach to Care of US Patients With Rheumatoid Arthritis.
    Harrold LR; Reed GW; John A; Barr CJ; Soe K; Magner R; Saunders KC; Ruderman EM; Haselkorn T; Greenberg JD; Gibofsky A; Harrington JT; Kremer JM
    Arthritis Care Res (Hoboken); 2018 Mar; 70(3):379-387. PubMed ID: 28544704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do Patients With Moderate or High Disease Activity Escalate Rheumatoid Arthritis Therapy According to Treat-to-Target Principles? Results From the Rheumatology Informatics System for Effectiveness Registry of the American College of Rheumatology.
    Yun H; Chen L; Xie F; Patel H; Boytsov N; Zhang X; Curtis JR
    Arthritis Care Res (Hoboken); 2020 Feb; 72(2):166-175. PubMed ID: 31566905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits and Sustainability of a Learning Collaborative for Implementation of Treat-to-Target in Rheumatoid Arthritis: Results of a Cluster-Randomized Controlled Phase II Clinical Trial.
    Solomon DH; Lu B; Yu Z; Corrigan C; Harrold LR; Smolen JS; Fraenkel L; Katz JN; Losina E
    Arthritis Care Res (Hoboken); 2018 Oct; 70(10):1551-1556. PubMed ID: 29316341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating Adherence to a Treat-to-Target Protocol in Recent-Onset Rheumatoid Arthritis: Reasons for Compliance and Hesitation.
    Markusse IM; Dirven L; Han KH; Ronday HK; de Sonnaville PB; Kerstens PJ; Lems WF; Huizinga TW; Allaart CF
    Arthritis Care Res (Hoboken); 2016 Apr; 68(4):446-53. PubMed ID: 26239288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treat-to-target in rheumatoid arthritis: Evaluating the patient perspective using the Patient Opinion Real-Time Anonymous Liaison system: The RA T2T PORTAL study.
    Benham H; Rutherford M; Kirby S; Stebbings S; White D; Sim D; Harrison A
    Int J Rheum Dis; 2019 May; 22(5):874-879. PubMed ID: 30793870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treat-to-target in rheumatology].
    Majdan M
    Wiad Lek; 2015; 68(3):259-64. PubMed ID: 26753210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group.
    Cohen S; Cannon GW; Schiff M; Weaver A; Fox R; Olsen N; Furst D; Sharp J; Moreland L; Caldwell J; Kaine J; Strand V
    Arthritis Rheum; 2001 Sep; 44(9):1984-92. PubMed ID: 11592358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Standardizing and personalizing the treat to target (T2T) approach for rheumatoid arthritis using the Patient-Reported Outcomes Measurement Information System (PROMIS): baseline findings on patient-centered treatment priorities.
    Bacalao EJ; Greene GJ; Beaumont JL; Eisenstein A; Muftic A; Mandelin AM; Cella D; Ruderman EM
    Clin Rheumatol; 2017 Aug; 36(8):1729-1736. PubMed ID: 28653263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treat-to-target biologic therapy in patients with rheumatoid arthritis is more efficacious and safe compared to delayed initiation of biologics: a real-world study.
    Lampropoulos CE; Orfanos P; Manoussakis MN; Tzioufas AG; Moutsopoulos HM; Vlachoyiannopoulos PG
    Clin Exp Rheumatol; 2017; 35(2):192-200. PubMed ID: 28094760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Criteria for improvement in rheumatoid arthritis: alternatives to the American College of Rheumatology 20.
    Albert DA; Huang G; Dubrow G; Brensinger CM; Berlin JA; Williams HJ
    J Rheumatol; 2004 May; 31(5):856-66. PubMed ID: 15124243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterising deviation from treat-to-target strategies for early rheumatoid arthritis: the first three years.
    Wabe N; Sorich MJ; Wechalekar MD; Cleland LG; McWilliams L; Lee A; Spargo L; Metcalf RG; Hall C; Proudman SM; Wiese MD
    Arthritis Res Ther; 2015 Mar; 17(1):48. PubMed ID: 25889527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort.
    Vermeer M; Kuper HH; Moens HJ; Drossaers-Bakker KW; van der Bijl AE; van Riel PL; van de Laar MA
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1219-26. PubMed ID: 23436821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
    Hørslev-Petersen K; Hetland ML; Junker P; Pødenphant J; Ellingsen T; Ahlquist P; Lindegaard H; Linauskas A; Schlemmer A; Dam MY; Hansen I; Horn HC; Ammitzbøll CG; Jørgensen A; Krintel SB; Raun J; Johansen JS; Østergaard M; Stengaard-Pedersen K;
    Ann Rheum Dis; 2014 Apr; 73(4):654-61. PubMed ID: 23434570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse Events and Resource Use Before and After Treat-to-Target in Rheumatoid Arthritis: A Post Hoc Analysis of a Randomized Controlled Trial.
    Solomon DH; Yu Z; Katz JN; Bitton A; Corrigan C; Fraenkel L; Harrold LR; Smolen JS; Losina E; Lu B
    Arthritis Care Res (Hoboken); 2019 Sep; 71(9):1243-1248. PubMed ID: 30221841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Design characteristics of the CORRONA CERTAIN study: a comparative effectiveness study of biologic agents for rheumatoid arthritis patients".
    Pappas DA; Kremer JM; Reed G; Greenberg JD; Curtis JR
    BMC Musculoskelet Disord; 2014 Apr; 15():113. PubMed ID: 24690143
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating rheumatoid arthritis to target: a Canadian physician survey.
    Haraoui B; Bensen W; Bessette L; Le Clercq S; Thorne C; Wade J
    J Rheumatol; 2012 May; 39(5):949-53. PubMed ID: 22467920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mixed methods study of clinicians' perspectives on barriers to implementation of treat to target in psoriatic arthritis.
    Dures E; Taylor J; Shepperd S; Mukherjee S; Robson J; Vlaev I; Walsh N; Coates LC
    Ann Rheum Dis; 2020 Aug; 79(8):1031-1036. PubMed ID: 32424031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating rheumatoid arthritis to target: a Canadian patient survey.
    Haraoui B; Bensen W; Thorne C; Wade J; Deamude M; Prince J; Légaré J
    J Clin Rheumatol; 2014 Mar; 20(2):61-7. PubMed ID: 24561407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Associations between the American College of Rheumatology pediatric response measures and the continuous measures of disease activity used in adult rheumatoid arthritis: a secondary analysis of clinical trial data from children with polyarticular-course juvenile idiopathic arthritis.
    Ringold S; Chon Y; Singer NG
    Arthritis Rheum; 2009 Dec; 60(12):3776-83. PubMed ID: 19950286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.